A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Bibliographic Details
Main Authors:	Hudis, Clifford, Swanton, Charles, Janjigian, Yelena Y, Lee, Ray, Sutherland, Stephanie, Lehman, Robert, Chandarlapaty, Sarat, Hamilton, Nicola, Gajria, Devika, Knowles, James, Shah, Jigna, Shannon, Keith, Tetteh, Ernestina, Sullivan, Daniel M, Moreno, Carolina, Yan, Li, Han, Hyo Sook
Format:	Online
Language:	English
Published:	BioMed Central 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979046/

Similar Items

Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin
by: Pant, Alok, et al.
Published: (2012)

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
by: Zhao, Yuan-Yuan, et al.
Published: (2014)

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
by: Chandarlapaty, Sarat, et al.
Published: (2009)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
by: Whicker, Margaret E., et al.
Published: (2016)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
by: Molife, L Rhoda, et al.
Published: (2014)

Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
by: Agarwal, Ekta, et al.
Published: (2014)

The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
by: Simioni, Carolina, et al.
Published: (2013)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
by: Doi, Toshihiko, et al.
Published: (2015)

Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells
by: Malkomes, Patrizia, et al.
Published: (2016)

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
by: Ahn, Daniel H., et al.
Published: (2015)

MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation
by: Jin, Piaopiao, et al.
Published: (2016)

PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
by: Qi, Lei, et al.
Published: (2015)

Erratum to: PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
by: Qi, Lei, et al.
Published: (2015)

Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206
by: Rehan, Mohd, et al.
Published: (2014)

Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis
by: Wilson, Jacob M, et al.
Published: (2015)

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
by: Komal Jhaveri, et al.
Published: (2017-08-01)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
by: Yu, Anthony F., et al.
Published: (2016)

Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility
by: Che, Huan-yong, et al.
Published: (2014)

The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner
by: Meng, Jieru, et al.
Published: (2013)

Adjuvant trastuzumab in HER2-positive breast cancer.
by: Slamon, D., et al.
Published: (2011)

Targeting HER2 in breast cancer: beyond trastuzumab
by: Winer, EP
Published: (2011)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
by: Nahta, Rita, et al.
Published: (2006)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
by: Modi, Shanu, et al.
Published: (2013)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
by: Palmieri, Carlo, et al.
Published: (2015)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
by: Fiszman, Gabriel L., et al.
Published: (2011)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
by: Jeyakumar, Alwin, et al.
Published: (2012)

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
by: Nahta, Rita
Published: (2012)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
by: Natoli, Clara, et al.
Published: (2013)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
by: Canonici, Alexandra, et al.
Published: (2013)

Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab
by: Sorscher, Steven
Published: (2013)

Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators
by: Scheer, Justin M., et al.
Published: (2012)

Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
by: Mann, K, et al.
Published: (2016)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
by: Sadeghi, Saeed, et al.
Published: (2014)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
by: Oostra, Drew R, et al.
Published: (2014)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Iqbal, Muhammad Shahid, et al.
Published: (2014)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
by: Callahan, Rena
Published: (2014)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo, Gonzalo, et al.
Published: (2016)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
by: Cheng, Huan, et al.
Published: (2014)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
by: Xin Li, et al.
Published: (2018-08-01)

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
by: Nafi, Siti Norasikin Mohd, et al.
Published: (2014)